Enzene Biosciences, the biotechnology subsidiary of Alkem Laboratories—one of India’s leading pharmaceutical companies—has established its first US-based manufacturing facility with a USD 70 million investment. Located in New Jersey, the site highlights Enzene’s commitment to expanding its global footprint and supporting biopharmaceutical innovation.

The new facility employs 50 staff to begin with, and plans are in place to scale the workforce to approximately 200. CEO Himanshu Gadgil underscored that Enzene’s proprietary continuous manufacturing technology, known as EnzeneX, is now operational in the United States, reflecting both the strength of India’s scientific ecosystem and the company’s ambition to provide transformative solutions on a global scale.

Continuous manufacturing offers significant advantages over traditional batch processing, delivering both speed and cost efficiencies. By extending this technology into the US, Enzene positions itself at the forefront of modern pharmaceutical manufacturing, while contributing to local industry growth and innovation.